Becotatug vedotin plus sintilimab for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of two drugs, becotatug vedotin and sintilimab, for patients with a type of nasopharyngeal cancer that has spread to nearby lymph nodes but not to distant organs. It aims to see if this treatment can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a type of nasopharyngeal cancer called non-keratinizing carcinoma (WHO type II or III).
- Your cancer has spread to certain lymph nodes (stage N2-3 or T4N1) but not to distant parts of the body.
- You have not had prior radiation or chemotherapy for this cancer.
- You are in relatively good health (ECOG score 0 or 1) and have adequate blood counts and organ function.
- You are willing to use effective birth control during treatment and for one year after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a drug called Becotatug Vedotin can help prevent nasopharyngeal cancer from returning in patients who have already completed standard treatments and are at high risk of recurrence.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemoradiation works better than chemoradiation alone for people with a specific type of advanced nasopharyngeal cancer. It aims to shrink tumors before surgery and prevent cancer from coming back.
This trial tests a new drug combination for people whose nasopharyngeal cancer has come back in the same area or nearby lymph nodes. The goal is to see if this treatment can shrink or control the cancer.
This trial tests two drugs—scipibaimab and tislelizumab—given together for people with nasopharyngeal cancer that has not responded to first-line platinum chemotherapy and a PD-1 inhibitor. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests whether giving an immunotherapy drug (sintilimab) combined with a pill chemotherapy (capecitabine) after standard treatment can help prevent nasopharyngeal cancer from coming back in people with high-risk stages. You must have already completed standard chemo-immunotherapy and radiation.
This trial tests a combination of low-dose radiation and immunotherapy (drugs that help your immune system fight cancer) for people with nasopharyngeal cancer that has spread to other parts of the body and who cannot receive chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.